Speech Treatment for Minimally Verbal Children With ASD and CAS

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
MGH Institute of Health Professions
Study ID
NCT05066178
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
5 Years - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • CAS Treatment for Minimally Verbal Children with Autism — BEHAVIORAL
    Treatment involves principles of motor learning embedded in a naturalistic developmental milieu

Study Details

Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.

Key Dates

Start date
May 1, 2024
Status verified
Mar 2026
Primary completion
Apr 30, 2030
Completion
Nov 30, 2030

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CAS Treatment for MV ASD
    Participants will receive CAS treatment, modified for minimally verbal children with autism

Primary Outcome Measure

Attempts Correct [ Time Frame: 5 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MGH Institute of Health ProfessionsBostonMassachusetts02129
Steve Meyer
[email protected]
617-726-2405
Karen Chenausky, PhD
[email protected]
Karen V Chenausky, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Autism spectrum disorder
By specialty
Pediatrics
By research site
MGH Institute of Health Professions· Boston, MA

Related Studies